CCL2 and hepatocellular carcinoma: GHJCD not only improved the microenvironment of HCC, including up-regulated the ratio of CD8+ T cells, down-regulated the ratio of Tregs, TAMs, and MDSCs, but also decreased the levels of inflammatory factors IL-6, IL-10, TNF-α, and CCl-2.